HBM Holdings' (HKG:2142) joint venture with Boston Children's Hospital, HBM Alpha Therapeutics, agreed to collaborate with an unnamed business partner to advance novel therapies targeting corticotropin-releasing hormone or CRH for multiple disorders.
Under the tie-up, the partner gets exclusive global rights to develop and commercialize HBM9013, an anti-CRH-neutralizing antibody. The license excludes China, Hong Kong, Taiwan and Macau.
In return, HBM Alpha will receive up to $395 million, including upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on future net product sales.
Additionally, HBM Alpha is entitled to a minority interest in the business partner, according to a Wednesday bourse filing.
HBM9013 is an antibody program developed by the group for CRH-related disorders, including congenital adrenal hyperplasia, a group of diseases caused by gene mutations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。